Erratum: Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial (American Journal of Transplantation (2012) 12(11) (3021–3030), (S1600613522271287), (10.1111/j.1600-6143.2012.04231.x));Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized, double-blind, multicenter controlled trial

American Journal of Transplantation

Volumn 12, Issue 11, 2012, Pages 3021-3030

  Winston, D J ^a   Saliba, F ^b   Blumberg, E ^c   Abouljoud, M ^d   Garcia Diaz, J B ^e   Goss, J A ^f   Clough, L ^g   Avery, R ^h   Limaye, A P ⁱ   Ericzon, B G ^j   Navasa, M ^k   Troisi, R I ^l   Chen, H ^m   Villano, S A ^m   Uknis, M E ^m  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Henry Ford Transplant Institute   (United States)

^e OCHSNER CLINIC FOUNDATION   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k HOSPITAL CLÍNIC   (Spain)

^l GHENT UNIVERSITY HOSPITAL   (Belgium)

^m ViroPharma Inc ^*  (United States)

more..

Author keywords

Cytomegalovirus; liver transplantation; Maribavir; prevention

Indexed keywords

EID: 84868200175     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12173     Document Type: Erratum

References (26)

1. Razonable RR,. Cytomegalovirus infection after liver transplantation. Current concepts and challenges. World J Gastroenterol 2008; 14: 4849-4860.
2. Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, Hellinger WC,. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant 2011; 11: 2181-2189.
3. Kornberg A, Grube T, Hommann M, Schotte U, Scheele J,. Cytomegalovirus infection after liver transplantation using different prophylaxes. Transplant Proc 2001; 33: 3624-3625.
4. Arthurs SK, Eid AJ, Pedersen RA, et al,. Delayed onset primary cytomegalovirus disease after liver transplantation. Liver Transplant 2007; 13: 1703-1709.
5. Gane E, Saliba F, Valdecassas GJ, et al,. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997; 350: 1729-1733.
6. Kalil AL, Levitsky J, Lyden E, Stoner J, Freifeld AG,. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-880.
7. Small LN, Lau J, Snydman DR,. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43: 869-880.
8. Kotton CN, Kumar D, Caliendo AM, et al,. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
9. Pescowitz MD, Rabkin J, Merion RM, et al,. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811-2815.
10. Paya C, Humar A, Dominguez E, et al,. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
11. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M,. Emergence of ganciclovir-resistant disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649.
12. Limaye AP, Raghu G, Koelle DM, Ferremberg J, Huang ML, Boeckh M,. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185: 20-27.
13. Biron KK, Harvey RJ, Chamberlain SC, et al,. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002; 46: 2365-2372.
14. Williams SL, Hartline CB, Kushner NL, et al,. In vitro activities of benzimidazole d- and l-ribonucleosides against herpes viruses. Antimicrob Agents Chemother 2003; 47: 2186-2192.
15. Drew WL, Miner RC, Marousek GI, Chou S,. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006; 37: 124-127.
16. Lalezari JP, Aberg JA, Wang LH, et al,. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 2002; 46: 2969-2976.
17. Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB,. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003; 47: 1334-1342.
18. Winston DJ, Young JA, Pullarkat V, et al,. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008; 111: 5403-5410
19. Protocol 1263-103, data on file. Viropharma, Inc. Exton, Pennsylvania.
20. Package insert, oral ganciclovir, 2003.
21. Swan SK, Smith WB, Marbury TC, et al,. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J Clin Pharmacol 2007; 47: 209-217.
22. Chou S,. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008; 18: 233-246.
23. Ljungman P, Griffiths P, Paya C,. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
24. Marty FM, Ljungman P, Papanicolaou GA, et al,. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: A phase 3, double-blind, placebo-controlled, randomized trial. Lancet 2011; 11: 284-292.
25. Humar A, Snydman D,. AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S78-S86.
26. Avery RK, Marty FM, Strasfeld L, et al,. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010; 12: 489-496.